Request Sample

Global Infantile Spasms Therapeutics Market Research Report 2022

SKU ID : QYR-21014363 | Publishing Date : 06-Jun-2022 | No. of pages : 88

Market Analysis and Insights: Global Infantile Spasms Therapeutics Market
An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life.
The global Infantile Spasms Therapeutics market size is projected to reach US$ 182.4 million by 2028, from US$ 142 million in 2021, at a CAGR of 3.6% during 2022-2028.
Global Infantile Spasms Therapeutics key players include Mallinckrodt, H. Lundbeck, etc. Global top two manufacturers hold a share over 60%.
In terms of product, Oral is the largest segment, with a share obout 55%. And in terms of application, the largest application is Hospital, followed by Clinic, etc.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Infantile Spasms Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Infantile Spasms Therapeutics market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Infantile Spasms Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Infantile Spasms Therapeutics market.
Global Infantile Spasms Therapeutics Scope and Market Size
Infantile Spasms Therapeutics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Infantile Spasms Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

Oral
Injection

Segment by Application

Hospital
Clinic
Other

By Region

North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company

Mallinckrodt
H. Lundbeck
Insys Therapeutics
Orphelia Pharma
Valerion Therapeutics
Catalyst Pharmaceuticals
Anavex Life Sciences
Retrophin
GW Pharmaceuticals

Frequently Asked Questions

This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
  • By product type
  • By End User/Applications
  • By Technology
  • By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.

Contact Information

24/7 Research Support

Phone: +1 (888) 690-5999

[email protected]